Javier Delgado
Overview
Explore the profile of Javier Delgado including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
844
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Delgado J, Reche R, Cianferoni D, Orlando G, van der Kant R, Rousseau F, et al.
Bioinformatics
. 2025 Feb;
41(2).
PMID: 39913370
Motivation: The FoldX force field was originally validated with a database of 1000 mutants at a time when there were few high-resolution structures. Here, we have manually curated a database...
2.
Bastos-Oreiro M, Iacoboni G, Garces V, Caballero A, Martinez N, Delgado J, et al.
Hemasphere
. 2025 Feb;
9(2):e70077.
PMID: 39906687
No abstract available.
3.
Iacoboni G, Navarro V, Sesques P, Rejeski K, Bastos-Oreiro M, Serpenti F, et al.
J Hematol Oncol
. 2024 Oct;
17(1):102.
PMID: 39468591
Chimeric antigen receptor (CAR) T-cell therapy fails to achieve durable responses in over 60% of relapsed/refractory (R/R) large B-cell lymphoma (LBCL) patients in the third or later line setting. After...
4.
Holtz A, Van Weyenbergh J, Hong S, Cuypers L, OToole A, Dudas G, et al.
BMC Infect Dis
. 2024 Oct;
24(1):1139.
PMID: 39390446
We investigate the emergence, mutation profile, and dissemination of SARS-CoV-2 lineage B.1.214.2, first identified in Belgium in January 2021. This variant, featuring a 3-amino acid insertion in the spike protein...
5.
Bailen R, Iacoboni G, Delgado J, Lopez-Corral L, Hernani-Morales R, Ortiz-Maldonado V, et al.
Transplant Cell Ther
. 2024 Jul;
30(10):988.e1-988.e11.
PMID: 39069076
Chimeric antigen receptor (CAR)-T cell therapy is approved for the treatment of relapsed/refractory (R/R) large B cell lymphoma (LBCL). However, elderly patients might not be candidates for this therapy due...
6.
Iacoboni G, Iraola-Truchuelo J, OReilly M, Navarro V, Menne T, Kwon M, et al.
Hemasphere
. 2024 May;
8(5):e62.
PMID: 38774657
Over 60% of relapsed/refractory (R/R) large B-cell lymphoma (LBCL) patients who receive chimeric antigen receptor (CAR) T cells will experience disease progression. There is no standard next line of therapy...
7.
Martinez-Martin I, Crousilles A, Ochoa J, Velazquez-Carreras D, Mortensen S, Herrero-Galan E, et al.
Cell Rep
. 2023 Dec;
42(12):113490.
PMID: 38052212
The underlying genetic defect in most cases of dilated cardiomyopathy (DCM), a common inherited heart disease, remains unknown. Intriguingly, many patients carry single missense variants of uncertain pathogenicity targeting the...
8.
Bastos-Oreiro M, Gutierrez A, Iacoboni G, Lopez Corral L, Reguera J, Abrisqueta P, et al.
Transplant Cell Ther
. 2023 Sep;
29(12):747.e1-747.e10.
PMID: 37659694
In the pre-chimeric antigen receptor T cell (CAR-T) therapy era, the SCHOLAR-1 study identified a group of patients with refractory aggressive B cell lymphoma (ABCL) with particularly poor prognoses. We...
9.
Gonzalez-Avila G, Sommer B, Garcia-Hernandez A, Ramos C, Delgado J, Vazquez L, et al.
J Oncol
. 2022 Oct;
2022:5349691.
PMID: 36213817
Several matrix metalloproteinases (MMPs) and psychological stress are associated with poor cancer prognosis. The current work goal was to determine MMPs' and stress hormones' blood concentrations from lung adenocarcinoma (LAC)...
10.
Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma
Kwon M, Iacoboni G, Reguera J, Lopez Corral L, Morales R, Ortiz-Maldonado V, et al.
Haematologica
. 2022 Jun;
108(1):110-121.
PMID: 35770532
Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are CD19-targeted chimeric antigen receptor (CAR) T cells approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). We performed a retrospective study to evaluate safety...